Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

32
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
32
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

75
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
75
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Spinal Cord Injury ll: Pathophysiology01:14

Spinal Cord Injury ll: Pathophysiology

47
Spinal cord injury progresses through two interconnected phases: primary injury and secondary injury.Primary InjuryPrimary injury happens at the moment of trauma and involves immediate mechanical damage to the spinal cord.Compression happens when broken vertebrae, herniated discs, or accumulating blood (such as a hematoma) press directly against the spinal cord, distorting its normal shape and function. In cases of contusion, the cord is bruised by a blunt force (like penetrating injuries or...
47
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

72
Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Lancet (London, England)·2026
Same author

ImmuSeeker: deep mining of immune-related gene family signatures through lineage reconstruction.

Genome biology·2026
Same author

Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer's disease pathology.

The journal of prevention of Alzheimer's disease·2026
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology.

Neurology. Clinical practice·2025

Related Experiment Video

Updated: May 6, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K

Multiple sclerosis: Five new things.

Jacqueline A Nicholas1, Aaron L Boster, Michael K Racke

  • 1The Ohio State University Department of Neurology, Columbus.

Neurology. Clinical Practice
|November 1, 2013
PubMed
Summary
This summary is machine-generated.

High salt intake may contribute to autoimmune diseases like multiple sclerosis (MS). New therapies, including dimethyl fumarate, show promise for MS treatment and management.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Related Experiment Videos

Last Updated: May 6, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Area of Science:

  • Neuroimmunology
  • Autoimmune Disease Research

Background:

  • Preliminary studies link high salt diet to autoimmune diseases, including multiple sclerosis (MS).
  • Emerging research explores novel therapeutic targets and strategies for MS management.

Purpose of the Study:

  • To summarize recent advancements in multiple sclerosis (MS) therapies and potential etiological factors.
  • To highlight new FDA-approved treatments and ongoing investigations for MS.

Main Methods:

  • Review of clinical trial results for new MS therapies.
  • Analysis of research identifying potential autoantigenic targets in MS.
  • Investigation into alternative dosing strategies for existing MS medications.

Main Results:

  • Dimethyl fumarate (BG-12) approved as an oral therapy for MS.
  • Alemtuzumab shows potential but is not yet FDA-approved for MS.
  • Alternative dosing for glatiramer acetate may improve patient outcomes.
  • KIR4.1 identified as a potential autoantigenic target in MS.

Conclusions:

  • Multiple sclerosis (MS) treatment landscape is evolving with new oral therapies and repurposed drugs.
  • Dietary factors like salt intake warrant further investigation in MS etiology.
  • Continued research into novel targets like KIR4.1 and optimized dosing strategies is crucial for advancing MS care.